# Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence

- Link: https://www.thailand-business-news.com/pr-news/nona-biosciences-appoints-dr-peng-wang-as-chief-operating-officer-to-advance-platform-capabilities-and-drive-operational-excellence
- Published: 2026-07-03T08:36:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., July 3, 2026 /PRNewswire/ — Nona Biosciences ("Nona" or the "Company"),
a global biotechnology company advancing biotherapeutic discovery through innovative
technology platforms, today announced the appointment of Dr. Peng Wang as Chief 
Operating Officer (COO). Dr. Wang will be based in Suzhou and report directly to
Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

In this role, Dr. Wang will be responsible for establishing an efficient and integrated
scientific research platform, rapidly building core technical capabilities, and 
upgrading the Company’s comprehensive and standardized scientific research service
system. He will lead efforts to realize lean and efficient resource management, 
with a focus on elevating overall project management efficiency to support Nona’s
growing portfolio of partner programs.

Dr. Wang brings over 15 years of extensive experience in biomedical research and
drug development. Prior to joining Nona, he served as Head of Biologics and _in 
vitro _APAC at Crown Bioscience. Before that, he held the position of Head of Antibody
Group at WuXi AppTec and served as a Senior Scientist at Roche. Dr. Wang began his
career with several years of postdoctoral research experience at the University 
of Pennsylvania.

"We are very pleased to welcome Dr. Peng Wang to Nona Biosciences at a pivotal time
as we continue to strengthen our platform capabilities and enhance our operational
infrastructure," said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. "
Peng’s deep expertise across biologics development, antibody discovery, and research
operations will be instrumental in formulating our long-term platform strategy and
ensuring the efficient execution of our project portfolio. I am confident that he
will fulfill his role to the best of his ability and maintain Nona’s high standard
of performance and delivery."

"Nona Biosciences has established itself as a leader in antibody discovery and engineering,
with its proprietary technology platforms and integrated I to I^(®) framework from
idea to IND," said Dr. Peng Wang, Chief Operating Officer of Nona Biosciences. "
I am excited to join the team and look forward to further enhancing our scientific
capabilities, streamlining operations, and delivering greater value to our partners."

Dr. Wang holds a Ph.D. in Molecular Biology from the University of Delaware.

**About Nona Biosciences**

Nona Biosciences is a global biotechnology company committed to advancing biotherapeutic
innovation through cutting-edge technology platforms and integrated solutions. Nona
supports programs with its I to I^(®) framework, from early-stage ideas through 
preclinical research and advancement toward IND and early clinic, spanning target
validation and antibody discovery to early development.

Nona’s proprietary Harbour Mice^(®) technology platform generates fully human monoclonal
antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-
only (HCAb) format. The HCAb Harbour Mice^(®) is the world’s first fully human HCAb
transgenic mouse with clinical validation. This unique platform offers exceptional
versatility for diverse applications using fully human VH single-domain antibodies
as a plug-and-play system, including bispecific antibodies, multi-specific antibodies,
CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice^(®), single-B cell screening technology, NonaCarFx™ (
a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery
platform), Modalities-on-Demand^(®) (a next-generation modalities solution), and
end-to-end preclinical drug development services, Nona Biosciences is dedicated 
to driving the global invention of transformative next-generation drugs. For more
information, please visit: [www.nonabio.com](https://www.nonabio.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence ](http://www.prnasia.com/story/archive/4997625_CN97625_0?rand=184833)